Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma

Severe eosinophilic asthma (SEA) is associated with high peripheral blood and airway eosinophilia, recurrent disease exacerbations and severe airflow limitation. Eosinophilic inflammation is also responsible for small airway disease (SAD) development. SEA patients experience poor disease control and...

Full description

Saved in:
Bibliographic Details
Main Authors: Angelantonio Maglio, Carolina Vitale, Simona Pellegrino, Cecilia Calabrese, Maria D’Amato, Antonio Molino, Corrado Pelaia, Massimo Triggiani, Girolamo Pelaia, Cristiana Stellato, Alessandro Vatrella
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
severe asthma
mepolizumab
eosinophils
lung function
FEF25-75
ACT
Biology (General)
QH301-705.5
Online Access:https://doaj.org/article/75cb49082e334b6f9ca52940d0d6f952
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/75cb49082e334b6f9ca52940d0d6f952

Similar Items